The global Radiodermatitis Market is estimated to be valued at Us$ 407.2 Mn in 2023 and is expected to exhibit a CAGR Of 4.3% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Radiodermatitis refers to skin inflammation caused by radiation therapy. The skin becomes red, sore and blistered during and after radiation therapy for cancer treatment. Cancer patients undergoing radiation therapy experience radiodermatitis as a side effect of radiation exposure. Products used for prevention and treatment of radiodermatitis include topical corticosteroids, antibiotics, hydrophilic creams and dressings made of hydrocolloid or alginate to protect damaged skin. These products help protect skin from further damage, relieve pain and promote healing during radiation therapy. With rising cancer incidence rates globally, radiation therapy is being used more often, driving increased demand for effective radiodermatitis treatments and prevention products.
Market key trends:
One of the key trends in the radiodermatitis market is the introduction of advanced dressings made of biomaterials instead of regular gauze dressings. These newer dressings effectively protect damaged skin, don’t require frequent dressing changes and help expedite healing. For example, Mepilex Ag, a barrier dressing made of silver-coated fibers, is widely used for radiodermatitis. It protects skin from external infectious agents and maintains a moist healing environment. With their superior efficacy over traditional products, advanced biomaterial dressings are gaining popularity among healthcare professionals. This growing preference for innovative biomaterial dressings is expected to significantly impact the radiodermatitis market over the forecast period.
Threat of new entrants: The radiodermatitis market is characterized by high R&D costs and regulatory requirements to get approval for new treatments which pose a significant threat of new entrants.
Bargaining power of buyers: There exist a moderately large number of treatment options for radiodermatitis which provide some bargaining power to the buyers but the serious nature of the condition maintains supplier’s power.
Bargaining power of suppliers: The key suppliers have established brand names and supply a range of related products which gives them a bargaining advantage over buyers.
Threat of new substitutes: New technological advancements related to radiation oncology and targeted therapies have potential to replace certain radiodermatitis treatment options.
Competitive rivalry: Acelity, Inc. (3M) has a major market share.
The global Radiodermatitis Market is expected to witness high growth, exhibiting CAGR of 4.3% over the forecast period, due to increasing adoption of radiotherapy as a treatment option for cancer patients.
Regional analysis: North America dominates the global radiodermatitis market due to the increasing adoption of advanced radiotherapy options and presence of major market players. Europe and Asia Pacific are expected to exhibit lucrative growth over the forecast period driven by rising healthcare spending and increasing awareness.
Key players: Key players operating in the radiodermatitis market are Acelity, Inc. (3M), BMG Pharma S.r.l., ConvaTec Group PLC, DermaSciences Inc. (Integra LifeSciences Holdings Corporation), Intermed Pharmaceuticals, M?lnlycke Health Care, Smith & Nephew Plc, Stratpharma AG, Kannalife, Inc., McKesson Corporation. The key players are focusing on product innovation and partnership strategies to strengthen their market presence.
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it